OLUMIANT (baricitinib)


Drug overview for OLUMIANT (baricitinib):

Generic name: baricitinib (BAR-i-SYE-ti-nib)
Drug class: Antirheumatic Agents (Biologic DMARDS)
Therapeutic class: Analgesic, Anti-inflammatory or Antipyretic

Baricitinib, a Janus kinase (JAK) inhibitor, is an immunomodulating agent and a disease-modifying antirheumatic drug (DMARD).

No enhanced Uses information available for this drug.
DRUG IMAGES
  • OLUMIANT 2 MG TABLET
    OLUMIANT 2 MG TABLET
The following indications for OLUMIANT (baricitinib) have been approved by the FDA:

Indications:
Adjunct therapy for COVID-19 requiring oxygen or ventilatory support
Alopecia areata
Rheumatoid arthritis


Professional Synonyms:
Adjunct therapy for 2019-nCoV disease requiring oxygen or ventilatory support
Adjunct therapy for SARS-CoV-2 infection requiring oxygen or ventilatory support
Areata alopecia
Arthritis deformans
Arthrosis deformans
Nodose rheumatism
Rheumatic arthritis
Rheumatic gout